Towards Healthcare
Genome Editing Market Size Drives 16.95% CAGR by 2034

Genome Editing Market Size, Trends, Forecasts & Opportunities

According to market projections, the genome editing sector is expected to grow from USD 9.39 billion in 2024 to USD 44.95 billion by 2034, reflecting a CAGR of 16.95%. Applications in various industries promote the growth of the genome editing market.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Genome Editing Market Assessment

  • Overview
  • Global Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • Global Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • Global Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • Global Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations
  • Global Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA

North America Genome Editing Market Assessment

  • Overview
  • North America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • North America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • North America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • North America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

Europe Genome Editing Market Assessment

  • Overview
  • Europe Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • Europe Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • Europe Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • Europe Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

Asia Pacific Genome Editing Market Assessment

  • Overview
  • Asia Pacific Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • Asia Pacific Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • Asia Pacific Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • Asia Pacific Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

Latin America Genome Editing Market Assessment

  • Overview
  • Latin America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • Latin America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • Latin America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • Latin America Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

MEA Genome Editing Market Assessment

  • Overview
  • MEA Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Genetic Engineering
      • Cell Line Engineering
      • Animal Genetic Engineering
      • Plant Genetic Engineering
      • Others
    • Clinical Applications
      • Diagnostics
      • Therapy Development
  • MEA Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Technology (2021 – 2033)
    • (CRISPR)/Cas9
    • TALENs/MegaTALs
    • ZFN
    • Meganuclease
    • Others
  • MEA Genome Editing Market Size Value (US$) and Volume (Billion Tons), by Delivery Method (2021 – 2033)
    • Ex-vivo
    • In-vivo
  • MEA Genome Editing Market Size Value (US$) and Volume (Billion Tons), by End-use (2021 – 2033)
    • Biotechnology and Pharmaceutical Companies
    • Academic and Government Research Institutes
    • Contract Research Organizations

Company Profiles

  • Thermo Fisher Scientific, Inc
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Lonza
  • Bluebird Bio, Inc.
  • OriGene Technologies, Inc.
  • New England Biolabs
  • Genscript Biotech Corp
  • Transposagen Biopharmaceuticals, Inc.
  • Danaher Corporation
  • Horizon Discovery Ltd. (Revvity, Inc.)
  • Takara Bio Inc.
  • AstraZeneca
  • Cellectis S.A.
  • Caribou Biosciences, Inc
  • Intellia Therapeutics, Inc.
  • CRISPR Therapeutics
  • Precision BioSciences
  • Editas Medicine
  • Sangamo Therapeutics
  • Recombinetics
  • Cibus Inc.
  • Merck KGaA

Conclusion & Recommendations

  • Insight Code: 5161
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Genetically engineered animal models of CVD have been made possible thanks to the development of CRISPR-based germline genome editing techniques. CRISPR-based gene editing techniques are quicker, simpler to use, and more widely applicable than traditional gene targeting methods that utilize embryonic stem cells.

In an effort to treat sickness or strengthen the body resistance to illness, gene therapy attempts to correct a damaged gene or replace it with a healthy one. Numerous illnesses, including cancer, AIDS, diabetes, heart disease, cystic fibrosis, and hemophilia, may benefit from it as a treatment.

World Health Organization, National Heart, Lung, and Blood Institute, FDA, The White House, USAD, Press Information Bureau.